Cryoglobulins occur with an incidence of approximately 6% in individuals with haematopoietic malignancies, connective tissue diseases, and chronic or acute infections.' The cryoglobulinaemias are classified into 3 groups: those containing monoclonal immunoglobulins (Igs), mixed cryoglobulins containing monoclonal Ig with antibody activity to polyclonal immunoglobulin G (IgG), and the polyclonal cryoglobulins containing 1 or more classes of Ig.2 The latter 2 types of cryoglobulins may contain rheumatoid factor activities, other autoantibody reactivities, complement components, and antigens reactive with the corresponding autoantibody.34
Possible factors responsible for the insolubility in the cold of monoclonal cryoimmunoglobulins (cryo-Igs) have recently been discerned by Middaugh et al. 7 They showed that the tertiary structure of cryo-Igs differs from soluble Igs and that the low temperature insolubility of cryo-Igs may be an intrinsic property of the structure which favours associations between cryo-Ig molecules. Although many factors have been studied which affect the Accepted for publication 25 We report here that plasma fibronectin (PFN) is a component of all the cryoglobulins tested. Fibronectin (FN) is a normal plasma constituent whose physical-chemical properties have been extensively studied.9 10 The molecule has a large molecular weight (440 000 daltons), probably consists of 2 identical subunits, and contains a small percentage of carbohydrate. FN is also a major constituent of the cell surface components of fibroblastic and endothelial cells, and the cell surface FN differs from PFN by being larger by approximately 10 was absorbed by incubation of 2 ml of the antiserum with 1 ml of glutaraldehyde-insolubilised gelatin. The RTA reaction mixtures consisted of 15 ,ud of 125L-PFN (specific activity approximately 80 000 cpm/ng), and anti-PEN serum diluted to titre in 1:100 diluted normal rabbit serum (300 1d) in PBS containing 1 % BSA. After incubation at 370C for 2 hours 40 1.l of the absorbed second antibody was added, and incubation was continued for 1 hour at 370C. The precipitates were removed by centrifugation at 1500 xg for 45 minutes and counted in a gamma counter. Known amounts of purified PFN were added to construct an inhibition curve, and varying amounts of dissolved cryoglobulins were quantitated for PFN concentration.
Results
The cryoglobulins in this study were defined as the portion of sera drawn and clotted at 370C which precipitated at 40C for 24 to 48 hours. The precipitated fractions showed differences in solubility, some readily dissolving on warming to 370C and others leaving small amounts of precipitate on warming to 560C or 370C in 1 M urea-PBS. Only the soluble portions were examined for their components. As shown in Table 1 , all of the PBS washed and dissolved fractions of the cryoglobulins contained a component which was reactive with antisera prepared to PFN. In addition, 17 of the 20 cryoglobulins tested for IgG contained that component. The cryoglobulin derived from the patient with Waldenstr6m's macroglobulinaemia was positive for IgM but not IgG or IgA. Several other cryo- In one experiment (Table 2) 125I-PFN was added to the freshly drawn serum from a patient with essential mixed cryoglobulinaemia and the 125I-PFN followed through stages of precipitation, solubilisation, and reprecipitation. As seen in the Table, 7'7y% of the total 125I-PFN remained in the cryoprecipitated fraction of serum.
If it is assumed that the original concentration of PFN in the serum was 150 ,ug/ml the precipitate would contain approximately 12 ,ug of PFN. The second and third PBS washes of the precipitate contained negligible counts, again showing that the PFN probably was not loosely adherent to other cryoglobulin components. When the redissolved first precipitate was allowed to precipitate in the cold, approximately 50°% of the 125I-PFN reprecipitated, and approximately 70% of the latter reprecipitated a third time. Thus, the PFN becomes insoluble in the cold with other cryoglobulin components after removal of other serum factors and solubilisation.
In a separate experiment a different serum was processed in the same manner and the PFN in the various fractions was quantitated by RIA. As can be seen in Table 2 , results were obtained which were similar to those as in the experiment where 125I_ PFN was added to serum. These results confirmed the observations that a fraction of PFN coprecipitated in the cold with the other components of cryoglobulins and that the PFN was reprecipitable in several cycles of precipitation-solubilisation.
Discussion
Cryoglobulins may consist of many components. In individuals with autoantibodies the cryoglobulins can include IgG or IgM with the autoantibody specificity; IgA and various complement components are also detectable." 15 Further, the purified PFN used in these studies remained soluble in PBS at concentrations of 0-2-0 8 mg/ml over extended periods of time at 40C. Therefore it would be expected that in the repeated precipitation-solubilisation experiments PFN would be removed from the cryoglobulin precipitates.
It will be of interest to determine to what component(s) of the cryoglobulins PFN is associated and also to ascertain if the presence of PFN affects the cryoprecipitability of cryoglobulins. These questions are being investigated. 
